Goldman Sachs’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Goldman Sachs’s Portfolio GRNA Stock Details GRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-150,579	Closed	-$44.9K	–	6057
2023 Q2	$44.9K	Buy	150,579 +88,446	+142%	+$26.7K	﹤0.01%	5475
2023 Q1	$26.9K	Sell	62,133 -14,945	-19%	-$11.5K	﹤0.01%	5636
2022 Q4	$91K	Buy	77,078 +47,996	+165%	+$78.2K	﹤0.01%	5502
2022 Q3	$67K	Buy	+29,082	New	+$76.1K	﹤0.01%	5765
2022 Q2	–	Sell	-26,807	Closed	-$258K	–	6845
2022 Q1	$258K	Buy	+26,807	New	+$240K	﹤0.01%	5743
2021 Q3	–	Sell	-333,889	Closed	-$3.27M	–	6608
2021 Q2	$3.27M	Buy	333,889 +196,489	+143%	+$1.92M	﹤0.01%	3740
2021 Q1	$1.33M	Buy	+137,400	New	+$1.35M	﹤0.01%	4385

Goldman Sachs's GRNA Position: Q3 2023 in Review

Goldman Sachs sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q3 2023, closing a stake of 150,579 shares — an estimated $44.9K sold.

Goldman Sachs first reported a position in GRNA in Q1 2021 and held it in 7 quarters. The position peaked at $3.27M in Q2 2021. 0 funds tracked by Wall St. Rank hold GRNA as of Q3 2023.

Goldman Sachs reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q3 2023 after selling out during the quarter.
Goldman Sachs sold 150,579 GreenLight Biosciences Holdings, PBC Common Stock shares in Q3 2023, an estimated $44.9K.
Goldman Sachs first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q1 2021 and held it in 7 quarters.
Goldman Sachs's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $3.27M in Q2 2021.
0 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q3 2023.

Based on Goldman Sachs's 13F filing for Q3 2023, filed 14 Nov 2023.